86 related articles for article (PubMed ID: 25486327)
1. RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects.
Kawata K; Morishita K; Nakayama M; Yamada S; Kobayashi T; Furusawa Y; Arimoto-Kobayashi S; Oohashi T; Makishima M; Naitou H; Ishitsubo E; Tokiwa H; Tai A; Kakuta H
J Med Chem; 2015 Jan; 58(2):912-26. PubMed ID: 25486327
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
Ohsawa F; Yamada S; Yakushiji N; Shinozaki R; Nakayama M; Kawata K; Hagaya M; Kobayashi T; Kohara K; Furusawa Y; Fujiwara C; Ohta Y; Makishima M; Naitou H; Tai A; Yoshikawa Y; Yasui H; Kakuta H
J Med Chem; 2013 Mar; 56(5):1865-77. PubMed ID: 23391145
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.
Kobayashi T; Furusawa Y; Yamada S; Akehi M; Takenaka F; Sasaki T; Akahoshi A; Hanada T; Matsuura E; Hirano H; Tai A; Kakuta H
ACS Med Chem Lett; 2015 Mar; 6(3):334-8. PubMed ID: 25815156
[TBL] [Abstract][Full Text] [Related]
4. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).
Takamatsu K; Takano A; Yakushiji N; Morohashi K; Morishita K; Matsuura N; Makishima M; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 May; 3(5):780-7. PubMed ID: 18297677
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice.
Kakuta H; Ohsawa F; Yamada S; Makishima M; Tai A; Yasui H; Yoshikawa Y
Biol Pharm Bull; 2012; 35(4):629-33. PubMed ID: 22466572
[TBL] [Abstract][Full Text] [Related]
6. [Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor].
Kakuta H
Yakugaku Zasshi; 2011; 131(6):917-23. PubMed ID: 21628978
[TBL] [Abstract][Full Text] [Related]
7. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of newly synthesized retinoid X receptor agonists possessing a 6-[N-ethyl-N-(3-alkoxy-4-isopropylphenyl)amino]nicotinic acid skeleton in rats.
Ogasawara A; Murakami Y; Yakushiji N; Ohsawa F; Kusaba J; Aiba T; Kurosaki Y; Kakuta H
Drug Dev Ind Pharm; 2011 Sep; 37(9):1060-7. PubMed ID: 21417609
[TBL] [Abstract][Full Text] [Related]
9. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Leibowitz MD; Ardecky RJ; Boehm MF; Broderick CL; Carfagna MA; Crombie DL; D'Arrigo J; Etgen GJ; Faul MM; Grese TA; Havel H; Hein NI; Heyman RA; Jolley D; Klausing K; Liu S; Mais DE; Mapes CM; Marschke KB; Michellys PY; Montrose-Rafizadeh C; Ogilvie KM; Pascual B; Rungta D; Tyhonas JS; Urcan MS; Wardlow M; Yumibe N; Reifel-Miller A
Endocrinology; 2006 Feb; 147(2):1044-53. PubMed ID: 16269450
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of
Shibahara O; Watanabe M; Yamada S; Akehi M; Sasaki T; Akahoshi A; Hanada T; Hirano H; Nakatani S; Nishioka H; Takeuchi Y; Kakuta H
J Med Chem; 2017 Aug; 60(16):7139-7145. PubMed ID: 28753292
[TBL] [Abstract][Full Text] [Related]
11. Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.
Michellys PY; Ardecky RJ; Chen JH; Crombie DL; Etgen GJ; Faul MM; Faulkner AL; Grese TA; Heyman RA; Karanewsky DS; Klausing K; Leibowitz MD; Liu S; Mais DA; Mapes CM; Marschke KB; Reifel-Miller A; Ogilvie KM; Rungta D; Thompson AW; Tyhonas JS; Boehm MF
J Med Chem; 2003 Jun; 46(13):2683-96. PubMed ID: 12801232
[TBL] [Abstract][Full Text] [Related]
12. Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
Ohsawa F; Morishita K; Yamada S; Makishima M; Kakuta H
ACS Med Chem Lett; 2010 Dec; 1(9):521-5. PubMed ID: 24900241
[TBL] [Abstract][Full Text] [Related]
13. Retinoid X receptor ligands: a patent review (2007 - 2013).
Yamada S; Kakuta H
Expert Opin Ther Pat; 2014 Apr; 24(4):443-52. PubMed ID: 24456080
[TBL] [Abstract][Full Text] [Related]
14. Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference: RXRalpha-preferential agonist possessing a sulfonamide moiety.
Takamatsu K; Takano A; Yakushiji N; Morishita K; Matsuura N; Makishima M; Ali HI; Akaho E; Tai A; Sasaki K; Kakuta H
ChemMedChem; 2008 Mar; 3(3):454-60. PubMed ID: 18157857
[TBL] [Abstract][Full Text] [Related]
15. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.
Fujii S; Ohsawa F; Yamada S; Shinozaki R; Fukai R; Makishima M; Enomoto S; Tai A; Kakuta H
Bioorg Med Chem Lett; 2010 Sep; 20(17):5139-42. PubMed ID: 20656484
[TBL] [Abstract][Full Text] [Related]
16. RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
Kakuta H; Yakushiji N; Shinozaki R; Ohsawa F; Yamada S; Ohta Y; Kawata K; Nakayama M; Hagaya M; Fujiwara C; Makishima M; Uno S; Tai A; Maehara A; Nakayama M; Oohashi T; Yasui H; Yoshikawa Y
ACS Med Chem Lett; 2012 May; 3(5):427-32. PubMed ID: 24900488
[TBL] [Abstract][Full Text] [Related]
17. Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia.
Lagu B; Lebedev R; Pio B; Yang M; Pelton PD
Bioorg Med Chem Lett; 2007 Jun; 17(12):3491-6. PubMed ID: 17490875
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB.
Nakayama M; Yamada S; Ohsawa F; Ohta Y; Kawata K; Makishima M; Kakuta H
ACS Med Chem Lett; 2011 Dec; 2(12):896-900. PubMed ID: 24900278
[TBL] [Abstract][Full Text] [Related]
19. A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation.
Morichika D; Miyahara N; Fujii U; Taniguchi A; Oda N; Senoo S; Kataoka M; Tanimoto M; Kakuta H; Kiura K; Maeda Y; Kanehiro A
Respir Res; 2019 Jan; 20(1):2. PubMed ID: 30606200
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
Michellys PY; Ardecky RJ; Chen JH; D'Arrigo J; Grese TA; Karanewsky DS; Leibowitz MD; Liu S; Mais DA; Mapes CM; Montrose-Rafizadeh C; Ogilvie KM; Reifel-Miller A; Rungta D; Thompson AW; Tyhonas JS; Boehm MF
J Med Chem; 2003 Sep; 46(19):4087-103. PubMed ID: 12954061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
